The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis

Biomarkers

Volumn 20, Issue 1, 2015, Pages 5-16

  Nobakht M Gh, B Fatemeh ^a,d   Aliannejad, Rasoul ^b   Rezaei Tavirani, Mostafa ^a   Taheri, Salman ^c   Oskouie, Afsaneh Arefi ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CHEMISTRY AND CHEMICAL ENGINEERING RESEARCH CENTER OF IRAN   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Mass spectrometry; Metabolomics; NMR spectroscopy

Indexed keywords

ACETIC ACID; ACETONE; ALANINE; AMINOADIPIC ACID; ARGININE; ASPARTIC ACID; CHOLINE; CHYLOMICRON; DIMETHYLGLYCINE; FORMIC ACID; GLUTAMINE; GLUTATHIONE; HIPPURIC ACID; HYDROXYBUTYRIC ACID; ISOLEUCINE; LACTIC ACID; LOW DENSITY LIPOPROTEIN; LYSINE; PHENYLALANINE; PHOSPHORYLCHOLINE; PROLINE; PYRUVIC ACID; SERINE; SUCCINIC ACID; TAURINE; TISSUE EXTRACT; TRIGONELLINE; TYROSINE; VALINE; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER;

AMNION FLUID; ASTHMA; BILE; BLOOD; BODY FLUID; CEREBROSPINAL FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; EXHALED BREATH CONDENSATE; GUT ASPIRATE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG LAVAGE; METABOLISM; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PLASMA; REVIEW; SALIVA; SEMINAL PLASMA; SERUM; SWEAT; SYNOVIAL FLUID; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINE; ANIMAL; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANIMALS; ASTHMA; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84921759167     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.983167     Document Type: Review

References (105)

1. Accordino R, Visentin A, Bordin A, et al. (2008). Long-term repeatability of exhaled breath condensate pH in asthma. Respir Med 102: 377-81.
2. Agustí AG, Sauleda J, Miralles C, et al. (2002). Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:485-9.
3. Aliverti A, MacKlem PT. (2008). The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles. J Appl Physiol 105:749-51.
4. Arakaki AK, Skolnick J, McDonald JF. (2008). Marker metabolites can be therapeutic targets as well. Nature 456:443.
5. Bala L, Ghoshal UC, Ghoshal U, et al. (2006). Malabsorption syndrome with and without small intestinal bacterial overgrowth: a study on upper-gut aspirate using 1H NMR spectroscopy. Magn Resonan Med 56:738-44.
6. Ballatori N, Krance SM, Notenboom S, et al. (2009). Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390:191-214.
7. Baritussio A. (2004). Lung surfactant, asthma, and allergens: a story in evolution. Am J Respir Crit Care Med 169:550-1.
8. Beckonert O, Keun HC, Ebbels TM, et al. (2007). Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2:2692-703.
9. Bekier E, Wyczółkowska J, Szyc H, Mas̈liński C. (1974). The inhibitory effect of nicotinamide on asthma-like symptoms and eosinophilia in guinea pigs, anaphylactic mast cell degranulation in mice, and histamine release from rat isolated peritoneal mast cells by compound 48/80. Int Arch Allergy Immunol 47:737-48.
10. Bertini I, Luchinat C, Miniati M, et al. (2013). Phenotyping COPD by 1H NMR metabolomics of exhaled breath condensate. Metabolomics 10:302-11.
11. Boisvert F-M, Richard S. (2004). Arginine methylation regulates the cytokine response. Mol Cell 15:492-4.
12. Bollard ME, Stanley EG, Lindon JC, et al. (2005). NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed 18:143-62.
13. Burgel P-R, Montani D, Danel C, et al. (2007). A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax 62: 153-61.
14. Burgel P, De Blic J, Chanez P, et al. (2009). Update on the roles of distal airways in asthma. Eur Respir Rev 18:80-95.
15. Cap P, Chládek J, Pehal F, et al. (2004). Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. Thorax 59:465-70.
16. Carraro S, Rezzi S, Reniero F, et al. (2007). Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 175:986-90.
17. Castellani C, Cuppens H, Macek Jr M, et al. (2008). Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cystic Fibrosis 7:179-96.
18. Clayton TA, Lindon JC, Cloarec O, et al. (2006). Pharmacometabonomic phenotyping and personalized drug treatment. Nature 440:1073-7.
19. Centers for Disease Control and Prevention (CDC). (2011). Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001-2009. MMWR Morb Mortal Wkly Rep 60:547.
20. Corraliza IM, Soler G, Eichmann K, Modolell M. (1995). Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun 206:667-73.
21. Crocker GH, Toth B, Jones JH. (2013). Combined effects of inspired oxygen, carbon dioxide, and carbon monoxide on oxygen transport and aerobic capacity. J Appl Physiol 115:643-52.
22. Czebe K, Barta I, Antus B, et al. (2008). Influence of condensing equipment and temperature on exhaled breath condensate pH, total protein and leukotriene concentrations. Respir Med 102:720-5.
23. Dallinga JW, Robroeks CM, Van Berkel JJ, et al. (2010). Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy 40:68-76.
24. De Laurentiis G, Paris D, Melck D, et al. (2008). Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J 32:1175-83.
25. Debigare R, Cote CH, Maltais F. (2001). Peripheral muscle wasting in chronic obstructive pulmonary disease: clinical relevance and mechanisms. Am J Respir Crit Care Med 164:1712-17.
26. Ellis DI, Dunn WB, Griffin JL, et al. (2007). Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 8:1243-66.
27. Erzurum SC, Gaston BM. (2012). Biomarkers in asthma: a real hope to better manage asthma. Clin Chest Med 33:459-71.
28. Fahy JV, Dickey BF. (2010). Airway mucus function and dysfunction. N Engl J Med 363:2233-47.
29. Fathi F, Ektefa F, Oskouie AA, et al. (2013a). NMR based metabonomics study on celiac disease in the blood serum. Gastroenterol Hepatol Bed Bench 6:190-4.
30. Fathi F, Kasmaee LM, Sohrabzadeh K, et al. (2014a). The differential diagnosis of Crohn's disease and celiac disease using nuclear magnetic resonance spectroscopy. Appl Magn Reson 45: 451-9.
31. Fathi F, Majari-Kasmaee L, Mani-Varnosfaderani A, et al. (2014b). 1H NMR based metabolic profiling in Crohn's disease by random forest methodology. Magn Reson Chem 52:370-6.
32. Fathi F, Oskouie AA, Tafazzoli M, et al. (2013b). Metabonomics based NMR in Crohn's disease applying PLS-DA. Gastroenterol Hepatol Bed Bench 6:S82-S86.
33. Flume PA, Mogayzel Jr PJ, Robinson KA, et al. (2010). Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 182:298-306.
34. Fogarty A, Britton J. (2000). The role of diet in the aetiology of asthma. Clin Exp Allergy 30:615-27.
35. Forsythe IJ, Wishart DS. (2009). Exploring human metabolites using the human metabolome database. Curr Protoc Bioinformatics 25: 14.8.1-14.8.45.
36. Freedman SD, Blanco PG, Zaman MM, et al. (2004). Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 350:560-9.
37. Gahleitner F, Guallar-Hoyas C, Beardsmore CS, et al. (2013). Metabolomics pilot study to identify volatile organic compound markers of childhood asthma in exhaled breath. Bioanalysis 5: 2239-47.
38. Godet C, Hira M, Adoun M, et al. (2001). Rapid diagnosis of alcoholic ketoacidosis by proton NMR. Intensive Care Med 27:785-6.
39. Gonen B, O'Donnell P, Post T, et al. (1987). Very low density lipoproteins (VLDL) trigger the release of histamine from human basophils. Biochim Biophys Acta (BBA) Lipids Lipid Metab 917: 418-24.
40. Gowda GN, Ijare OB, Somashekar B, et al. (2006). Single-step analysis of individual conjugated bile acids in human bile using 1H NMR spectroscopy. Lipids 41:591-603.
41. Griffin JL, Kauppinen RA. (2007). Tumour metabolomics in animal models of human cancer. J Proteome Res 6:498-505.
42. Ho WE, Xu YJ, Xu F, et al. (2013). Metabolomics reveals altered metabolic pathways in experimental asthma. Am J Respir Cell Mol Biol 48:204-11.
43. Hogg JC. (2004). Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364:709-21.
44. Horvath I, Hunt J, Barnes P. (2005). Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 26:523-48.
45. Hudson VM. (2001). Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 30:1440-61.
46. Hudson VM. (2004). New insights into the pathogenesis of cystic fibrosis. Treat Respir Med 3:353-63.
47. Ibrahim B, Marsden P, Smith J, et al. (2013). Breath metabolomic profiling by nuclear magnetic resonance spectroscopy in asthma. Allergy 68:1050-6.
48. Izquierdo-García JL, Puerto-Nevado L, Peces-Barba G, et al. (2010). A metabonomic approach to evaluate COPD in a model of cigarette smoke exposure in mice. Metabolomics 6:564-73.
49. Joseloff E, Sha W, Bell SC, et al. (2014). Serum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis. Pediatr Pulmonol 49:463-72.
50. Jung J, Kim SH, Lee HS, et al. (2013). Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin Exp Allergy 43:425-33.
51. Kharitonov SA, Barnes PJ. (2001). Exhaled markers of inflammation. Curr Opin Allergy Clin Immunol 1:217-24.
52. Kim M-A, Shin YS, Pham LD, Park H-S. (2014). Adult asthma biomarkers. Curr Opin Allergy Clin Immunol 14:49-54.
53. Knuffman JE, Sorkness CA, Lemanske Jr RF, et al. (2009). Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 123:411-16.
54. Kullmann T, Barta I, Antus B, et al. (2008). Environmental temperature and relative humidity influence exhaled breath condensate pH. Eur Respir J 31:474-5.
55. Lacey ME, Subramanian R, Olson DL, et al. (1999). High-resolution NMR spectroscopy of sample volumes from 1 nL to 10 μL. Chem Rev 99:3133-52.
56. Lara A, Khatri SB, Wang Z, et al. (2008). Alterations of the arginine metabolome in asthma. Am J Respir Crit Care Med 178: 673-81.
57. Lindon JC. (2003). HPLC-NMR-MS: past, present and future. Drug Discov Today 8:1021-2.
58. MacEachran DP, Ye S, Bomberger JM, et al. (2007). The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect Immun 75:3902-12.
59. Mador MJ, Bozkanat E. (2001). Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res 2:216-24.
60. Major HJ, Williams R, Wilson AJ, Wilson ID. (2006). A metabonomic analysis of plasma from Zucker rat strains using gas chromatography/mass spectrometry and pattern recognition. Rapid Commun Mass Spectrom 20:3295-302.
61. Maniscalco M, De Laurentiis G, Pentella C, et al. (2006). Exhaled breath condensate as matrix for toluene detection: a preliminary study. Biomarkers 11:233-40.
62. Mathers CD, Loncar D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442.
63. Mattarucchi E, Baraldi E, Guillou C. (2012). Metabolomics applied to urine samples in childhood asthma; differentiation between asthma phenotypes and identification of relevant metabolites. Biomed Chromatogr 26:89-94.
64. McClay JL, Adkins DE, Isern NG, et al. (2010). 1H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J Proteome Res 9: 3083-90.
65. Mehta A, Arora N, Gaur S, Singh B. (2009). Choline supplementation reduces oxidative stress in mouse model of allergic airway disease. Eur J Clin Investig 39:934-41.
66. Mehta AK, Singh BP, Arora N, Gaur SN. (2010). Choline attenuates immune inflammation and suppresses oxidative stress in patients with asthma. Immunobiology 215:527-34.
67. Mena-Bravo A, Luque De Castro M. (2014). Sweat: a sample with limited present applications and promising future in metabolomics. J Pharm Biomed Anal 90:139-47.
68. Modolell M, Corraliza IM, Link F, et al. (1995). Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrowderived macrophages by TH 1 and TH 2 cytokines. Eur J Immunol 25: 1101-4.
69. Montuschi P, Paris D, Melck D, et al. (2012). NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. Thorax 67:222-8.
70. Nicholson JK, Lindon JC. (2008). Systems biology: metabonomics. Nature 455:1054-6.
71. Paige M, Burdick MD, Kim S, et al. (2011). Pilot analysis of the plasma metabolite profiles associated with emphysematous Chronic Obstructive Pulmonary Disease phenotype. Biochem Biophys Res Commun 413:588-93.
72. Puente-Maestu L, Perez-Parra J, Godoy R, et al. (2009). Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients. Eur Respir J 33:1045-52.
73. Raftery D. (2004). High-throughput NMR spectroscopy. Anal Bioanal Chem 378:1403-4.
74. Robroeks CM, Van Berkel JJ, Dallinga JW, et al. (2010). Metabolomics of volatile organic compounds in cystic fibrosis patients and controls. Pediatr Res 68:75-80.
75. Rodríguez DA, Alcarraz-Vizán G, Díaz-Moralli S, et al. (2011). Plasma metabolic profile in COPD patients: effects of exercise and endurance training. Metabolomics 8:508-16.
76. Saliba A, Nascimento D, Silva M, et al. (2005). Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cell Microbiol 7:1811-22.
77. Sato H, Feix JB, Hillard CJ, Frank DW. (2005). Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU. J Bacteriol 187:1192-5.
78. Saude EJ, Lacy P, Musat-Marcu S, et al. (2004). NMR analysis of neutrophil activation in sputum samples from patients with cystic fibrosis. Magn Reson Med 52:807-14.
79. Saude EJ, Obiefuna IP, Somorjai RL, et al. (2009). Metabolomic biomarkers in a model of asthma exacerbation: urine nuclear magnetic resonance. Am J Respir Crit Care Med 179:25-34.
80. Saude EJ, Skappak CD, Regush S, et al. (2011). Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol 127:757-64.e1-6.
81. Servetnyk Z, Krjukova J, Gaston B, et al. (2006). Activation of chloride transport in CF airway epithelial cell lines and primary CF nasal epithelial cells by S-nitrosoglutathione. Respir Res 7:124.
82. Slupsky CM, Cheypesh A, Chao DV, et al. (2009). Streptococcus pneumoniae and Staphylococcus aureus pneumonia induce distinct metabolic responses. J Proteome Res 8:3029-36.
83. Sofia M, Maniscalco M, De Laurentiis G, et al. (2011). Exploring airway diseases by NMR-based metabonomics: a review of application to exhaled breath condensate. J Biomed Biotechnol 2011:403260.
84. Soga T. (2007). Capillary electrophoresis-mass spectrometry for metabolomics. Methods Mol Biol 358:129-37.
85. Tiddens HA, Donaldson SH, Rosenfeld M, Pare PD. (2010). Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively? Pediatr Pulmonol 45:107-17
86. Tom A, Nair KS. (2006). Assessment of branched-chain amino acid status and potential for biomarkers. J Nutr 136:324S-30S.
87. Twomey KB, O'Connell OJ, McCarthy Y, et al. (2011). Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa. ISME J 6: 939-50.
88. Ubhi BK, Cheng KK, Dong J, et al. (2012a). Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst 8:3125-33.
89. Ubhi BK, Riley JH, Shaw PA, et al. (2012b). Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 40: 345-55.
90. Van der Greef J, Smilde AK. (2005). Symbiosis of chemometrics and metabolomics: past, present, and future. J Chemometr 19:376-86.
91. Vance RE, Hong S, Gronert K, et al. (2004). The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci USA 101:2135-9.
92. Vestbo J, Anderson W, Coxson HO, et al. (2008). Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 31:869-73.
93. Villas-Boas SG, Mas S, A˚kesson M, et al. (2005). Mass spectrometry in metabolome analysis. Mass Spectrom Rev 24:613-46.
94. Waddell JA, Emerson PA, Gunstone R. (1967). Hypoxia in bronchial asthma. Br Med J 2:402.
95. Wang T, Carroll W, Lenny W, et al. (2006). The analysis of 1-propanol and 2-propanol in humid air samples using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom 20:125-30.
96. Wetmore DR, Joseloff E, Pilewski J, et al. (2010). Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells. J Biol Chem 285:30516-22.
97. Wilson ID, Nicholson JK, Castro-Perez J, et al. (2005a). High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res 4:591-8.
98. Wilson ID, Plumb R, Granger J, et al. (2005b). HPLC-MSbased methods for the study of metabonomics. J Chromatogr B 817: 67-76.
99. Wolak JE, Esther Jr CR, O'Connell TM. (2009). Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers 14:55-60.
100. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. (2009). Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc 6:638-47
101. Yang J, Eiserich JP, Cross CE, et al. (2012). Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radic Biol Med 53:160-71.
102. Young V, Munro H. (1978). Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. Fed Proc 37:2291-300.
103. Zaman K, Carraro S, Doherty J, et al. (2006). S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol 70:1435-42.
104. Zhang A, Sun H, Wang P, et al. (2012). Modern analytical techniques in metabolomics analysis. Analyst 137:293-300.
105. Zhang X, Wei D, Yap Y, et al. (2007). Mass spectrometry-based ''omics'' technologies in cancer diagnostics. Mass Spectrom Rev 26: 403-31.